Friday, November 6, 2015

News: Implanet: Substantial Increase in Q3 2015 Revenue: +42% to €1,693 Thousand

BORDEAUX, France & BOSTON--()--Regulatory News:
Image result for Implanet
IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for the 3rd quarter, and nine months through 30 September 2015.

Ludovic Lastennet, CEO of Implanet, states: “The revenue and fine performance over the third quarter represent the continued sharp rise of our JAZZ activity in the United States. The interest shown during the recent SRS and NASS international scientific congresses show that our technology is providing an innovative solution to the challenges associated with spinal fusion surgery, both for patients and for surgeons . We are confident that our growth will continue, driven by our financial resources and continued marketing expansion in the world’s most dynamic markets, notably in the United States and Latin America.
Revenue (in € thousands - IFRS) 2015 2014 Change
1st quarter revenue 1,599 2,047 -21.9%
2nd quarter revenue 1,707 1,954 -12.6%
Spine (JAZZ) 790 393 +101%
Knee + Arthroscopy 903 795 +14%
Hip - - -
Total 3rd quarter revenue 1,693 1,188 +42%
Spine (JAZZ) 2,245 1,272 +76%
Knee + Arthroscopy 2,754 3,152 -13%
Hip - 765 -
9-month revenue 4,999 5,189 -4%
9-month revenue - excluding Hip 4,999 4,424 +13%
Implanet recorded a first-rate performance in Q3 2015, with revenue up +42% to €1,693 thousand. Spine activity (JAZZ) generated buoyant growth, doubling over the quarter (+101%) to €790 thousand, accounting for 47% of total sales, compared with 24% of revenue in Q3 2014. This growth was driven by the positive results recorded in the United States, a market on which quarterly revenue was multiplied by 4.5 (+352%) to €468 thousand, accounting for 59% of total JAZZ sales.
Over the first 9 months of the year, Group sales totaled €4,999 thousand, a slight decrease of 4%, due to the residual impact of the discontinuation of Hip activity in Q2 2014. Excluding Hip activity, revenue for the first 9 months of 2015 was up +13% (€4,999 thousand in 2015 vs. €4,424 thousand in 2014).
Year to date the JAZZ growth has been +76%. The largest contributor is the United States, with growth of +158% to €1,014 thousand, with France and the rest of the world continuing to generate solid growth levels of +51% and +26%, to €733 thousand and €394 thousand respectively.
As of 30 September 2015, the Group had sold 771 JAZZ units in the United States, 1,951 in France and 1,684 in the rest of the world, giving a year to date total of 4,406 units. This represents volume growth of +44%. This includes the 10,000th JAZZ sold, announced in a recent release.

The return to growth in Knee activity, a +14% increase in revenue to €903 thousand in Q3 2015, stabilized this segment and minimized the 9 month growth impact to -13%, to €2,754 thousand. As expected, Knee activity accounts for a decreasing share of the revenue mix, with Implanet’s strategic development focused in Spine.
IMPLANET will participate in the following Q4 2015 scientific congresses:
SILACOS, in Lima from 28 to 30 October 2015.
SOFCOT, in Paris from 10 to 12 November 2015.
CBOT, in Sao Paulo from 19 to 21 November 2015
MATSS Technical courses, in Ribeirao Preto (Brazil) from 27 to 28 November 2015.

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

Contacts

IMPLANET
Ludovic Lastennet, Tel.: +33 (0)5 57 99 55 55
CEO
or
NewCap
Investor Relations
Florent Alba, Tel.: +33 (0)1 44 71 94 94
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98

Published at BusinessWire

No comments:

Post a Comment